Amivantamab Plus Lazertinib Improves PFS Irrespective of Risk in EGFR-Mutant NSCLC
BrECADD Regimen Improves PFS vs eBEACOPP Regimen in Advanced Classical Hodgkin Lymphoma
Sifting Through Data in Lung Cancer and Leukemia: Drs Levy and Saint Fleur
Updated MANIFEST-2 Data With Pelabresib/Ruxolitinib Support Paradigm Shift in Myelofibrosis